|
End-of-day quote
Korea S.E.
2026-08-24
|
5-day change | 1st Jan Change | ||
| 4,240.00 KRW | +0.83% |
|
-8.23% | -38.37% |
| 04-13 | Genome & Company announced that it has received KRW 6.99999414 billion in funding | CI |
| 04-02 | Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding | CI |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
: Breakdown by Business Segment
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
Pharmaceuticals | 451M | 14.08B | 14.3B | 27.74B | - | ||
Total Assets | 137B | 173B | 162B | 147B | - | ||
Interest Expense | -54.92M | -175M | -1.74B | -3.54B | - | ||
Income Tax Expense | - | -1.08B | -1.2B | -1.37B | - | ||
CAPEX | -3.38B | -7.28B | -18.85B | -3.97B | - | ||
EBT | -36B | -58.03B | -51.85B | -28.21B | - | ||
D&A | 2.59B | 9.46B | 8.27B | 7.45B | - | ||
Net Income | -34.12B | -51.84B | -47.47B | -20.11B | - |
Geographical Revenue Distribution History
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
Oceania | - | - | - | 10.96M | - | ||
North America | - | - | - | 9.6B | - | ||
South America | - | - | - | 29.46M | - | ||
Europe | - | - | - | 7.37B | - | ||
Asia | - | - | - | 4.43B | - | ||
South Korea | 451M | 14.08B | 14.3B | 6.3B | - | ||
Total Assets | 137B | 173B | 162B | - | - | ||
Interest Expense | -54.92M | -175M | -1.74B | - | - | ||
Income Tax Expense | - | -1.08B | -1.2B | - | - | ||
D&A | 2.59B | 9.46B | 8.27B | - | - | ||
CAPEX | -3.38B | -7.28B | -18.85B | - | - | ||
Net Income | -34.12B | -51.84B | -47.47B | - | - | ||
EBT | -36B | -58.03B | -51.85B | - | - |
- Stock Market
- Stocks
- A314130 Stock
- Financials Genome & Company
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
